EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Typhoid Fever - Pipeline Review, H1 2017

  • ID: 4091097
  • Report
  • February 2017
  • 41 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Nanotherapeutics Inc
  • Prokarium Ltd
  • Protein Potential LLC
  • Sanofi Pasteur SA
  • MORE
Typhoid Fever - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Typhoid Fever - Pipeline Review, H1 2017, provides an overview of the Typhoid Fever (Infectious Disease) pipeline landscape.

Typhoid fever is an infection that causes diarrhea and a rash. It is most commonly due to a type of bacterium called Salmonella typhi (S. typhi). Symptoms include abdominal tenderness, agitation, chills, delirium, hallucinations, severe fatigue and weakness. Treatment includes antibiotics and supportive therapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Typhoid Fever - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Typhoid Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Typhoid Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Typhoid Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 1, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Typhoid Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Typhoid Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Typhoid Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Typhoid Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Typhoid Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Typhoid Fever (Infectious Disease).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Typhoid Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Typhoid Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Nanotherapeutics Inc
  • Prokarium Ltd
  • Protein Potential LLC
  • Sanofi Pasteur SA
  • MORE
Introduction

Typhoid Fever - Overview

Typhoid Fever - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Typhoid Fever - Therapeutics Assessment

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Typhoid Fever - Companies Involved in Therapeutics Development

GlaxoSmithKline Plc

Indian Immunologicals Ltd

Nanotherapeutics Inc

Prokarium Ltd

Protein Potential LLC

Sanofi Pasteur SA

Shantha Biotechnics Ltd

SK Chemicals Co Ltd

Zydus Cadila Healthcare Ltd

Typhoid Fever - Drug Profiles

(paratyphoid (bivalent) + typhoid) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(paratyphoid + typhoid) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(shigella + typhoid) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Streptococcal pneumonia + typhoid) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Typhella - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid Vi polysaccharide [strain S typhi Ty2] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ViCRM-197 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Typhoid Fever - Dormant Projects

Typhoid Fever - Discontinued Products

Typhoid Fever - Product Development Milestones

Featured News & Press Releases

Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of Typhoid Fever Vaccine

Jun 23, 2011: Sanofi Pasteur’s Typhim Vi Receives Prequalification From World Health Organization

Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate

Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine

Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine

Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study

Nov 29, 1994: Food And Drug Administration Grants License For A New Typhoid Fever Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Typhoid Fever, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Typhoid Fever - Pipeline by GlaxoSmithKline Plc, H1

Typhoid Fever - Pipeline by Indian Immunologicals Ltd, H1

Typhoid Fever - Pipeline by Nanotherapeutics Inc, H1

Typhoid Fever - Pipeline by Prokarium Ltd, H1

Typhoid Fever - Pipeline by Protein Potential LLC, H1

Typhoid Fever - Pipeline by Sanofi Pasteur SA, H1

Typhoid Fever - Pipeline by Shantha Biotechnics Ltd, H1

Typhoid Fever - Pipeline by SK Chemicals Co Ltd, H1

Typhoid Fever - Pipeline by Zydus Cadila Healthcare Ltd, H1

Typhoid Fever - Dormant Projects, H1

Typhoid Fever - Discontinued Products, H1

List of Figures:

Number of Products under Development for Typhoid Fever, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Nanotherapeutics Inc
  • Prokarium Ltd
  • Protein Potential LLC
  • Sanofi Pasteur SA
  • Shantha Biotechnics Ltd
  • SK Chemicals Co Ltd
  • Zydus Cadila Healthcare Ltd
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll